Q2 2024 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Reduced by Analyst
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Equities researchers at Zacks Research cut their Q2 2024 EPS estimates for Halozyme Therapeutics in a research note issued to investors on Wednesday, February 7th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.81 per share for the quarter, down […]
More Stories
Domino’s Pizza, Inc. (NYSE:DPZ) Short Interest Update
Domino’s Pizza, Inc. (NYSE:DPZ – Get Free Report) saw a large increase in short interest in October. As of October...
Climb Global Solutions, Inc. (NASDAQ:CLMB) Short Interest Update
Climb Global Solutions, Inc. (NASDAQ:CLMB – Get Free Report) was the target of a significant increase in short interest during...
CF Acquisition Corp. VII (NASDAQ:CFFS) Sees Large Drop in Short Interest
CF Acquisition Corp. VII (NASDAQ:CFFS – Get Free Report) was the recipient of a large decline in short interest during...
ConnectOne Bancorp, Inc. (NASDAQ:CNOB) Short Interest Down 19.5% in October
ConnectOne Bancorp, Inc. (NASDAQ:CNOB – Get Free Report) saw a large drop in short interest in October. As of October...
Diploma PLC (OTCMKTS:DPLMF) Short Interest Up 21.8% in October
Diploma PLC (OTCMKTS:DPLMF – Get Free Report) was the recipient of a large increase in short interest in the month...
Short Interest in The Crypto Company (OTCMKTS:CRCW) Drops By 20.5%
The Crypto Company (OTCMKTS:CRCW – Get Free Report) was the recipient of a significant decline in short interest during the...